• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高水平的二十碳五烯酸与冠状动脉 CTA 测量的冠状动脉周围脂肪组织衰减程度降低相关。

High levels of eicosapentaenoic acid are associated with lower pericoronary adipose tissue attenuation as measured by coronary CTA.

机构信息

Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology, Erlangen, Germany.

Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology, Erlangen, Germany.

出版信息

Atherosclerosis. 2021 Jan;316:73-78. doi: 10.1016/j.atherosclerosis.2020.10.006. Epub 2020 Oct 10.

DOI:10.1016/j.atherosclerosis.2020.10.006
PMID:33129586
Abstract

BACKGROUND AND AIMS

Higher pericoronary adipose tissue (PCAT) attenuation, a novel marker of inflammation in coronary CT angiography (CTA), has been shown to indicate increased cardiac mortality. Supplementation of eicosapentaenoic acid (EPA) has been shown to decrease cardiovascular death. Whether blood levels of n-3 fatty acids are associated with differences in PCAT attenuation is unknown.

METHODS

This is a cross-sectional analysis including 64 symptomatic patients who underwent coronary CTA. PCAT attenuation was measured in Hounsfield Units (HU) around the proximal 40 mm of the right coronary artery using semi-automated software. Erythrocyte membrane fatty acid composition was analyzed using gas chromatography. Individual fatty acids were expressed as a percentage of total identified fatty acids.

RESULTS

The patient cohort was divided into two groups using the median PCAT attenuation of -78.1 HU (each n = 32). No differences were seen in age, sex, BMI or traditional cardiovascular risk factors (CVRF) between groups (all p > 0.05). In univariable analysis, significantly higher values of EPA (1.00% [0.78; 1.26] vs. 0.78% [0.63; 0.99]; p = 0.02) were seen in patients with lower PCAT attenuation. All other fatty acids showed no differences (all p > 0.05). Moreover, a significant negative correlation was seen between PCAT attenuation and EPA (CC: 0.38; p = 0.002). In multivariable analysis, an inverse association of EPA with PCAT attenuation existed (ß = -0.31, p = 0.017), independent of age, gender, BMI and number of CVRF (all p > 0.1).

CONCLUSIONS

High levels of EPA are associated with lower PCAT attenuation on coronary CTA. This may indicate a different composition of pericoronary adipose tissue, potentially caused by a lower degree of coronary inflammation.

摘要

背景与目的

在冠状动脉 CT 血管造影(CTA)中,较高的冠状动脉周围脂肪组织(PCAT)衰减值是炎症的一个新标志物,已被证明与增加的心脏死亡率有关。补充二十碳五烯酸(EPA)已被证明可降低心血管死亡率。血液中 n-3 脂肪酸水平是否与 PCAT 衰减值的差异有关尚不清楚。

方法

这是一项横断面分析,纳入了 64 名接受冠状动脉 CTA 的有症状患者。使用半自动软件,在右冠状动脉近端 40mm 处的周围测量 PCAT 衰减值,以亨氏单位(HU)表示。使用气相色谱法分析红细胞膜脂肪酸组成。个体脂肪酸以总鉴定脂肪酸的百分比表示。

结果

根据 -78.1 HU 的中位 PCAT 衰减值将患者队列分为两组(每组 n=32)。两组间的年龄、性别、BMI 或传统心血管危险因素(CVRF)无差异(均 p>0.05)。在单变量分析中,PCAT 衰减值较低的患者 EPA 值明显较高(1.00%[0.78;1.26]比 0.78%[0.63;0.99];p=0.02)。所有其他脂肪酸均无差异(均 p>0.05)。此外,还观察到 PCAT 衰减值与 EPA 之间存在显著负相关(CC:0.38;p=0.002)。在多变量分析中,EPA 与 PCAT 衰减值之间存在反向关联(β=-0.31,p=0.017),独立于年龄、性别、BMI 和 CVRF 数量(均 p>0.1)。

结论

高 EPA 水平与冠状动脉 CTA 上较低的 PCAT 衰减值相关。这可能表明冠状动脉周围脂肪组织的组成不同,可能是由于冠状动脉炎症程度较低所致。

相似文献

1
High levels of eicosapentaenoic acid are associated with lower pericoronary adipose tissue attenuation as measured by coronary CTA.高水平的二十碳五烯酸与冠状动脉 CTA 测量的冠状动脉周围脂肪组织衰减程度降低相关。
Atherosclerosis. 2021 Jan;316:73-78. doi: 10.1016/j.atherosclerosis.2020.10.006. Epub 2020 Oct 10.
2
High pericoronary adipose tissue attenuation on computed tomography angiography predicts cardiovascular events in patients with type 2 diabetes mellitus: post-hoc analysis from a prospective cohort study.冠状动脉周围脂肪组织 CT 血管造影衰减程度高可预测 2 型糖尿病患者的心血管事件:前瞻性队列研究的事后分析。
Cardiovasc Diabetol. 2022 Mar 18;21(1):44. doi: 10.1186/s12933-022-01478-9.
3
Pericoronary Adipose Tissue Computed Tomography Attenuation and High-Risk Plaque Characteristics in Acute Coronary Syndrome Compared With Stable Coronary Artery Disease.对比稳定型冠心病,急性冠状动脉综合征患者的冠状动脉旁脂肪组织 CT 衰减值与高危斑块特征。
JAMA Cardiol. 2018 Sep 1;3(9):858-863. doi: 10.1001/jamacardio.2018.1997.
4
Relationship between changes in pericoronary adipose tissue attenuation and coronary plaque burden quantified from coronary computed tomography angiography.基于冠状动脉 CT 血管造影定量评估的冠状动脉斑块负荷与冠状动脉脂肪衰减变化的关系。
Eur Heart J Cardiovasc Imaging. 2019 Jun 1;20(6):636-643. doi: 10.1093/ehjci/jez013.
5
Association between higher pericoronary adipose tissue attenuation measured by coronary computed tomography angiography and nonalcoholic fatty liver disease: A matched case-control study.冠状动脉计算机断层血管造影测量的较高冠状动脉脂肪组织衰减与非酒精性脂肪肝的关系:一项匹配的病例对照研究。
Medicine (Baltimore). 2021 Aug 27;100(34):e27043. doi: 10.1097/MD.0000000000027043.
6
Pericoronary adipose tissue computed tomography attenuation distinguishes different stages of coronary artery disease: a cross-sectional study.冠状动脉周围脂肪组织 CT 衰减可区分不同阶段的冠状动脉疾病:一项横断面研究。
Eur Heart J Cardiovasc Imaging. 2021 Feb 22;22(3):298-306. doi: 10.1093/ehjci/jeaa224.
7
Pericoronary adipose tissue CT attenuation and its association with serum levels of atherosclerosis-relevant inflammatory mediators, coronary calcification and major adverse cardiac events.冠状动脉周围脂肪组织 CT 衰减值及其与动脉粥样硬化相关炎症介质、冠状动脉钙化和主要不良心脏事件的血清水平的相关性。
J Cardiovasc Comput Tomogr. 2021 Sep-Oct;15(5):449-454. doi: 10.1016/j.jcct.2021.03.005. Epub 2021 Apr 3.
8
Pericoronary adipose tissue and quantitative global non-calcified plaque characteristics from CT angiography do not differ in matched South Asian, East Asian and European-origin Caucasian patients with stable chest pain.经 CT 血管造影检查,在有稳定胸痛的匹配南亚裔、东亚裔和欧洲裔白种人患者中,冠状动脉周围脂肪组织和定量整体非钙化斑块特征并无差异。
Eur J Radiol. 2020 Apr;125:108874. doi: 10.1016/j.ejrad.2020.108874. Epub 2020 Feb 7.
9
Coronary inflammation based on pericoronary adipose tissue attenuation in type 2 diabetic mellitus: effect of diabetes management.基于 2 型糖尿病患者冠状动脉脂肪衰减的冠状动脉炎症:糖尿病管理的影响。
Cardiovasc Diabetol. 2024 Mar 29;23(1):108. doi: 10.1186/s12933-024-02199-x.
10
Prognostic value of pericoronary adipose tissue attenuation in patients with non-alcoholic fatty liver disease with suspected coronary artery disease.非酒精性脂肪性肝病合并疑似冠状动脉疾病患者冠状动脉周围脂肪组织衰减的预后价值
Heart Vessels. 2022 Dec;37(12):1977-1984. doi: 10.1007/s00380-022-02107-x. Epub 2022 Jun 7.

引用本文的文献

1
Pericoronary adipose tissue attenuation on coronary computed tomography angiography: Possibilities and challenges.冠状动脉计算机断层扫描血管造影术上的冠状动脉周围脂肪组织衰减:可能性与挑战
Atherosclerosis. 2025 Mar;402:119105. doi: 10.1016/j.atherosclerosis.2025.119105. Epub 2025 Jan 31.
2
Coronary microvascular dysfunction as a chronic inflammatory state: Is there a role for omega-3 fatty acid treatment?作为一种慢性炎症状态的冠状动脉微血管功能障碍:ω-3脂肪酸治疗是否起作用?
Am Heart J Plus. 2022 Jan 30;13:100098. doi: 10.1016/j.ahjo.2022.100098. eCollection 2022 Jan.
3
Association of mean pericoronary adipose tissue attenuation with different demographic factors in a subgroup of patients without coronary artery disease stratified by sex, body mass index, and age.
在按性别、体重指数和年龄分层的无冠状动脉疾病患者亚组中,平均冠状动脉周围脂肪组织衰减与不同人口统计学因素的关联。
Quant Imaging Med Surg. 2024 Jan 3;14(1):503-513. doi: 10.21037/qims-23-951. Epub 2024 Jan 2.
4
The Effects of Omega 3 and Omega 6 Fatty Acids on Glucose Metabolism: An Updated Review.ω-3 和 ω-6 脂肪酸对葡萄糖代谢的影响:最新综述。
Nutrients. 2023 Jun 8;15(12):2672. doi: 10.3390/nu15122672.
5
Association of perivascular fat attenuation on computed tomography and heart failure with preserved ejection fraction.CT 扫描中血管周围脂肪衰减与射血分数保留型心力衰竭的相关性。
ESC Heart Fail. 2023 Aug;10(4):2447-2457. doi: 10.1002/ehf2.14419. Epub 2023 May 31.
6
Diabetic dyslipidemia impairs coronary collateral formation: An update.糖尿病血脂异常损害冠状动脉侧支循环形成:最新进展。
Front Cardiovasc Med. 2022 Aug 22;9:956086. doi: 10.3389/fcvm.2022.956086. eCollection 2022.
7
Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial).有症状的女性冠状动脉微血管功能障碍患者中的特异性促解决介质(来自女性缺血试验以减少非阻塞性 CAD 中的事件[WARRIOR]试验)。
Am J Cardiol. 2022 Jan 1;162:1-5. doi: 10.1016/j.amjcard.2021.09.015. Epub 2021 Oct 30.